Q-omics provides the consensus-scored C2CD4B profile across patient tissues and cancer cell-line models. C2CD4B expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, C2CD4B is differentially expressed in 14, with the highest sampling consensus in HNSC. Additionally, C2CD4B RNA expression shows 14,559 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight UVM, HNSC, and PDAC as cancer lineages where C2CD4B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for C2CD4B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes C2CD4B survival associations across molecular data types. C2CD4B RNA expression shows survival associations in the most cancer types (22), followed by mutation status (1) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible C2CD4B RNA expression–survival associations across cancer types. High C2CD4B expression shows unfavorable associations in UVM and LGG, but favorable associations in CESC, READ, MESO and HNSC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify UVM as the clearest survival context for C2CD4B RNA expression.
This table summarizes C2CD4B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for C2CD4B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. C2CD4B shows lower tumor expression in HNSC, BLCA, KICH, KIRP and BRCA and higher tumor expression in THCA. The HNSC box plot shows higher C2CD4B RNA expression in normal versus tumor tissue (log2 FC = −0.800, t-test p = .001).
This table shows molecular features associated with C2CD4B in patient tissues and cancer cell lines. In patient samples, C2CD4B shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, C2CD4B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and LARGE_INTESTINE.
